Please assess the completion status of the following clinical trial:

Trial Title: Arginase Inhibition in Ischemia-reperfusion Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Coronary artery disease~Exclusion Criteria:~* Age \>80 years, Myocardial infarction/unstable angina within 6 weeks prior to the study, Raynaud's phenomenon, peripheral vasculopathies, arterial shunting or other vascular surgery of the study arm, Any concomitant disease or condition that may interfere with the possibility for the patient to comply with or complete the study protocol, Participant in an ongoing study, Unwillingness to participate following oral and written information.

- Gender: MALE
- Minimum Age: None
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- N-hydroxy-nor-arginine (Type: EXPERIMENTAL): N-hydroxy-nor-arginine 0.1 mg/ min i.a. for 20 min
- NaCl (Type: PLACEBO_COMPARATOR): NaCl 0.9%, 6 ml/min i.a. for 20 min

Based on this trial design, predict the completion outcome and termination type (if applicable).